A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DRSP / drospirenone

[Related PubMed/MEDLINE]
Total Number of Papers: 151
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DRSP  (>> Co-occurring Abbreviation)
Long Form:   drospirenone
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. CPA, DSG, FAI, HA, LNG, OCs, PCOS, RIES, SHBG
2020 A direct comparison of the transcriptional activities of progestins used in contraception and menopausal hormone therapy via the mineralocorticoid receptor. ETG, GES, LNG, MHT, MPA, MR, NES, NETA, NOMAC
2020 Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg. ---
2020 Burden of Menstrual Pain Measured by Heatmap Visualization of Daily Patient-Reported Data in Japanese Patients Treated with Ethinylestradiol/Drospirenone: A Randomized Controlled Study. EE
2020 Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone). CMA, OCs, PCOS
2020 Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. AUC, EE, PK
2020 Comparison of change in body weight between contraception containing 30-mug ethinylestradiol/2-mg chlormadinone acetate or 30-mug ethinylestradiol/3-mg drospirenone: a randomised controlled trial. CMA, COC, EE
2020 Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception. POPs
2020 Drospirenone: a novel progestogen used as an oral contraceptive without an estrogen component. FDA
10  2020 Effects of oral contraceptives on serum concentrations of adipokines and adiposity indices of women with polycystic ovary syndrome: a randomized controlled trial. BMI, BRI, CPA, DSG, LAP, LNG, OCs, PCOS, VAI, WC, WHR, WHtR
11  2020 Effects of oral contraceptives on the quality of life of women with polycystic ovary syndrome: a crossover randomized controlled trial. CPA, DSG, LNG, OCs, PCOS, QOL
12  2020 Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime. ---
13  2020 Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome. CMA, COC, DNG, EE, PCOS, SHBG
14  2020 Mechanical and Physical Behavior of Fibrin Clot Formation and Lysis in Combined Oral Contraceptive Users. COCs, EE, PPP, TEG, VTE
15  2020 Menopausal hyperinsulinism and hypertension - new approach. ApoA, apoB, AUC, BMI, DHEAS, FSH, HDL, HOMA, LDL, LH, OGTT, PRL, SHBG
16  2020 Serum Metabolome Changes in Relation to Prothrombotic State Induced by Combined Oral Contraceptives with Drospirenone and Ethinylestradiol. COCs, EE
17  2019 A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4mg over nine cycles in comparison with desogestrel 0.075mg. ---
18  2019 Combined oral contraceptive in female mice causes hyperinsulinemia due to beta-cell hypersecretion and reduction in insulin clearance. COC, CTL, EE
19  2019 Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone. COC, CON, EE/DRSP, EE/LN, IR, IR
20  2019 Effects of different progestins on prostaglandin biosynthesis in human endometrial explants. CMA, COX-2, DEX, DNG, IL-1beta, mRNA, PGF2 alpha
21  2019 Effects of drospirenone and norethisterone acetate combined with estradiol on mammographic density and proliferation of breast epithelial cells-A prospective randomized trial. NETA
22  2019 Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. ---
23  2018 A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. CMA, EE, OCs, OD
24  2018 Effects of combined oral contraception containing drospirenone on premenstrual exacerbation of Meniere's disease: Preliminary study. EE
25  2018 Maintaining physiologic testosterone levels during combined oral contraceptives by adding dehydroepiandrosterone: II. Effects on sexual function. A phase II randomized, double-blind, placebo-controlled study. DHEA, EE, FSFI, LNG, OCs, SFD, SSAQ, VPA
26  2018 The Impact of Two Combined Oral Contraceptives Containing Ethinyl Estradiol and Drospirenone on Whole Blood Clot Viscoelasticity and the Biophysical and Biochemical Characteristics of Erythrocytes. COC, EE, SEM, TEG
27  2017 A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome. BMI, CPA, DSG, FAI, FSH, HDL-C, HOMA-IR, LDL-C, LH, PCOS, SHBG, TC, TG
28  2017 Effect of hormone replacement therapy with the anti-mineralocorticoid progestin Drospirenone compared to tibolone on endothelial function and central haemodynamics in post-menopausal women. RH
29  2017 Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins. BMI, BP, CA, DSG, FBG, HDL-C, HOMA-IR, LDL-C, OC, OCs, PCOS, TG
30  2017 Efficacy and safety of drospirenone 2 mg/17beta-estradiol 1 mg hormone therapy in Korean postmenopausal women. ---
31  2017 Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. DNG, LNG
32  2017 Hormonal contraception: venous and arterial disease. HCs, LNG, VTE
33  2017 Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. SHBG
34  2016 Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA). LNG
35  2016 Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. ATE, HRT, HRT
36  2016 Effects of drospirenone on adhesion molecule expression and monocyte adherence in human endothelial cells. HUVECs, MPA
37  2016 Fourth-Generation Progestins Inhibit 3beta-Hydroxysteroid Dehydrogenase Type 2 and Modulate the Biosynthesis of Endogenous Steroids. NES, NOMAC
38  2016 Hormonal therapy with estradiol and drospirenone improves endothelium-dependent vasodilation in the coronary bed of ovariectomized spontaneously hypertensive rats. ERalpha, SHAM
39  2016 Progestin isoforms provide different levels of protein S expression in HepG2 cells. COCs, LNG, Pol II, PS, VTE
40  2016 The effect of a drospirenone-containing combined oral contraceptive on female sexual function: a prospective randomised study. BCM, CI, COCs, EE, FSFI, NFPM, OR
41  2015 Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study. BC, BP, BW, CS, ECW, FM, HOMA-IR, HRT, ICW, IR, KI, MENQoL, NETA, PMW
42  2015 Drospirenone enhances GPIb-IX-V-mediated platelet activation. ADP, APTT, FIB, GPIb-IX-V, PGRMC1, PT, TT, vWF
43  2015 Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. PI
44  2015 Effects of two contraceptives containing drospirenone on blood pressure in normotensive women: a randomized-controlled trial. BP, DBP, EE
45  2015 Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review. COCs, DNG, EE, LNG, NOMAC, VTE
46  2015 Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study. EE
47  2015 Nomegestrol acetate/17-beta estradiol: a review of efficacy, safety, and patient acceptability. COC, EE, LNG, NOMAC
48  2015 Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial. CI, COC, DSG, EE, HFI, LNG, PBO
49  2015 Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol. EE, KTZ
50  2015 Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects. AD, ADG, COCs, DHEA, DHEAS, EE, FTI, SHBG
51  2015 Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects. COCs, DHEA, EE, MDQ, Q-LES-Q
52  2015 Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. EE, LNG
53  2014 Comparison of the impact of four generations of progestins on hemostatic variables. COCs, FVIII, NGM, PAI-1
54  2014 Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. EE
55  2014 Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive. EE
56  2014 Influence of an oral contraceptive containing drospirenone on insulin sensitivity of healthy women. EE, OCs, SI
57  2014 Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. HF, MR, UCP1, WAT
58  2013 A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms. DSG, DSG, EE, WHAQ
59  2013 A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris. EE, IGA, SGA
60  2013 Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study. BW, EE, PK
61  2013 Combined hormonal contraceptives and the risk of venous and arterial thromboembolism and cardiovascular death: misuse of automated databases. ATE, EE, FDA
62  2013 Combined oral contraceptive containing drospirenone does not modify 24-h ambulatory blood pressure but increases heart rate in healthy young women: prospective study. EE, OCs
63  2013 Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. EE, PCOS
64  2013 Evaluation of the in vitro release and pharmacokinetics of parenteral injectable formulations for steroids. MCSs
65  2013 The bioequivalence of the contraceptive steroids ethinylestradiol and drospirenone is not affected by co-administration of dehydroepiandrosterone. COC, DHEA, EE, LNG
66  2013 The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive. COCs, DHEA, DHEA-S, EE, PD, PK
67  2012 A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. CO, COCs, EE, HR, TPR
68  2012 A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 mug/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 mug/drospirenone 3 mg administered in a 24/4 regimen. EE, OC
69  2012 Combination of injectable ethinyl estradiol and drospirenone drug-delivery systems and characterization of their in vitro release. EE, PBCA, PLGA
70  2012 Contraceptive efficacy and tolerability of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study. EE, MIB
71  2012 Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens. COCs, CPA, EE, mFGS
72  2012 Drospirenone and levonorgestrel in combination with either 30 or 20 mcg ethinylestradiol reduce soluble adhesion molecules in Brazilian women; cross-sectional study. EE, ICAM-1, LNG, VCAM-1
73  2012 Efficacy of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. EE
74  2012 Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study. EE, RBC
75  2012 Long-term tolerability of ethinylestradiol 20 mug/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study. AE, EE, MIB
76  2012 Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women. EE
77  2012 Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells. CMA, DSG, DYD, LNG, MPA, NET, NOM, PGRMC1
78  2012 Sexual behavior and oral contraception: a pilot study. EE, MFSQ, OCs, PI
79  2012 Skin improvement with two different oestroprogestins in patients affected by acne and polycystic ovary syndrome: clinical and instrumental evaluation. CMA, EE, EPs, PCOS, TEWL
80  2011 Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. MR
81  2011 Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women. HRT
82  2011 Contraceptive efficacy of a combined oral contraceptive containing ethinyloestradiol 20 mug/drospirenone 3mg administered in a 24/4 regimen: a pooled analysis of four open-label studies. CI, EE, PI
83  2011 Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 mug compared with a 21/7 regimen of desogestrel 150 mug/ethinylestradiol 20 mug: a pooled analysis. COC, DSG, EE
84  2011 Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. GF, HMECs, LNG, MPA
85  2011 Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. COC, EE, NOMAC
86  2011 Metabolic effects of contraceptive steroids. DNG, EE, NES, NOMAC, TMG
87  2011 New insight on a possible mechanism of progestogens in terms of breast cancer risk. MPA, NET, PGRMC1
88  2011 Nomegestrol acetate: steroid receptor transactivation profile in Chinese hamster ovary cells and ovulation inhibition in rat and monkey. DNG, GR, LNG, MR, NOMAC, PRB
89  2011 Parenteral oil-based drospirenone microcrystal suspensions-evaluation of physicochemical stability and influence of stabilising agents. MCS
90  2011 Plasma leptin and adiponectin levels in hormone replacement therapy and contraception: effects of different progestogens. EE, NETA
91  2011 Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mug plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis. COC, EE
92  2011 Types of progestogens in combined oral contraception: effectiveness and side-effects. CI, COC, DSG, RR
93  2011 Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment-related resources. DRSP/EE, EE
94  2010 Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study. EE
95  2010 Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. CMA, DHEAS, DSG, EE, GSD, OCs, PCOS, SHBG
96  2010 Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol. EE, FSH, LH, NOMAC
97  2010 Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne. OCs
98  2010 Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. COC, DSG, EE, MDQ
99  2010 Hormone therapy for the management of menopausal symptoms: pharmacotherapy update. CHD, HT, WHI
100  2010 The use of newer progestins for contraception. DNG, EE, GR, NES, NOMAC, PR, TMG